These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10932606)

  • 1. New clinical trials for the treatment of neuroendocrine tumors.
    Bajetta E; Bichisao E; Artale S; Celio L; Ferrari L; Di Bartolomeo M; Zilembo N; Stani SC; Buzzoni R
    Q J Nucl Med; 2000 Mar; 44(1):96-101. PubMed ID: 10932606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
    De Martino MC; Hofland LJ; Lamberts SW
    Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of carcinoid tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):863-77. PubMed ID: 14686708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in chemotherapy and biotherapy of endocrine tumors.
    Oberg K
    Curr Opin Oncol; 1998 Jan; 10(1):58-65. PubMed ID: 9466486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art and future prospects in the management of neuroendocrine tumors.
    Oberg K
    Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
    Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
    Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
    Kulke MH
    Endocr Relat Cancer; 2007 Jun; 14(2):207-19. PubMed ID: 17639038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
    Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
    Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine tumors of the digestive system].
    Prónai L; Rácz K; Tulassay Z
    Orv Hetil; 2002 May; 143(19 Suppl):1081-6. PubMed ID: 12063866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary neuroendocrine/carcinoid tumors: a review article.
    Bertino EM; Confer PD; Colonna JE; Ross P; Otterson GA
    Cancer; 2009 Oct; 115(19):4434-41. PubMed ID: 19562772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
    Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
    Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
    Kvols LK; Woltering EA
    Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.
    Unek IT; Celtik A; Yener S; Yavuzsen T; Alacacioglu A; Cokmert S; Oztop I; Demirkan B; Dicle O; Sagol O; Bekis R; Yilmaz U
    J BUON; 2009; 14(1):135-8. PubMed ID: 19365885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
    Forrer F; Valkema R; Kwekkeboom DJ; de Jong M; Krenning EP
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):111-29. PubMed ID: 17382268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.